Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Humble and Fred April8 2021

<< Previous

Bullboard Posts

Next >>

Comment by Hideawayon Apr 14, 2021 12:02pm

187 Views

Post# 32993056

RE:RE:RE:RE:Humble and Fred April8 2021

I've been invested in ate for years and and agree that one has to have patience with junior biotechs.However,my expectations was that we would see a bit more upward share price by now.Meeting timelines and transparency are the two categories that I look for when determining what action to take with juniors.I am somewhat disappointed with ate in achieving these markers.But,the science is compelling enough to keep holding for now.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China